# Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma

> **NCT06825546** · PHASE2 · RECRUITING · sponsor: **Sir Run Run Shaw Hospital** · enrollment: 70 (estimated)

## Conditions studied

- Advanced Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Icaritin
- **DRUG:** AG chemotherapy

## Key facts

- **NCT ID:** NCT06825546
- **Lead sponsor:** Sir Run Run Shaw Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06825546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06825546, "Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06825546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*